

PROTOCOL FOR PREVENTION & KILL CORONA VIRUS, OR MANAGEMENT OF COVID-19 WITH THE HELP OF DRY HEAT , TRAMADOL+PARACETAMOL, IMMUNOBOSTER ETC.

*NILESH KUSHWAH¹, MANISH KUSHWAH ², MUKUL SARATHE ³, SUMIT PAL⁴

DEPARTMENT OF PHARMACY M.pharma (pharmacology) 2nd semester/1st year¹

Clinical research associate trainee in CLINOCARE CR¹.

DEPARTMENT OF PHARMACY M.pharma (pharmaceutical chemistry) 2nd semester/1st year²

DEPARTMENT OF PHARMACY B.Pharm (Pharmacy) 8th semester/4th year ³

SAGAR INSTITUTE OF RESEARCH AND TECHNOLOGY (SIRT-P) Bhopal MP India ¹

SAGAR Institute Of science and technology (SISTec.) BHOPAL MP. India ²

Kailash Narayan Patidar College of Pharmacy, Misrod Bhopal M.P. India ³

V.N.S COLLEGE OF PHARMACY BHOPAL MP INDIA ⁴

ABSTRACT: In this situations we are suffering from Nobel Corona virus pandemic & Today is Very important to fight & bravery to Corona virus. Corona virus comes in India 2020 . In second pick is very dangerous to fight covid-19, in present 2021 daily cases comes in India 3,000,00+ / day. & Some vaccines are developed by the pharmaceutical company. ***But my thoughts is different*** I want to kill Corona virus with the help of dry heat during entering Corona virus (0-8days). It's a invocation periods & we can easily kill Corona virus. Then some drug's use for prevent Corona virus symptoms & increase immune system by IMMUNOBOSTER. Because Corona virus transmitted through nasal route & mouth in the form of water drops. After study I observe in Corona virus present Ace-2 receptor. But we can destroy Ace-2 receptor by the dry heat.

KEYWORDS: CORONA VIRUS, DRY HEAT, PARACETAMOL, TRAMADOL, IMMUNOBOSTER, AVIPTADIL.

INTRODUCTION: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus in year 2019 in Burhan China is called (Corona virus 2019 disease). Most people infected with the COVID-19 virus & still we are unable to cure Corona virus. will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people above age 45-50 years, and those with underlying medical problems like- cardiovascular disease (CVS), diabetes (DM), chronic respiratory disease (CRD), & develop serious illness. The best way to prevent and cure or slow down transmission person to person is to be well informed about the COVID-19 virus, The Corona virus spreads primarily through saliva droplets or discharge from the nose when an infected person coughs or

sneezes, so it's important that you also practice respiratory etiquette. Major attack on lungs and respiratory tract.

SYMPTOMS:-

- Fever
- Panache/ headache
- Weakness
- Coughing
- Sneezing
- Problem in breathing /short breath

One formula for easy identify in Normal disease and Corona virus disease

- 1.) Fever, sneezing, coughing, weakness, panache, is called Normal disease

FEVER, SNEEZING, COUGHING, WEAKNESS, PANACHE, **PROBLEM IN BREATHING** is called as covid-19. Include pulse rate is decrease & oxygen level also decrease in Corona patients we observed

TREATMENT/ PREVENTION:- still we are unable to cure 100% patients. But some medicine are used to treat Corona virus and management like- paracetamol for normal fever, amoxicillin use for treat various bacterial infections, vitamin C , hydroxychloroquine etc. But specific treatment is not available still in future we discover new molecule for treatment Corona virus.

Gargle also use for management covid-19

Dry heat :- if we can inhalation dry heat the Corona virus definitely kill in respiratory tract (temperature 60-100C°) for three days interval 6 Hours. Because in dry heat water is absent and virus transmitted by the droplets. If we inhale dry heat for continuously 3 days virus kill in nasal cavity. And this method is very easy to handle everyone and cheaply.

BENEFITS:-

- Easy handle
- Cheaply
- Available everywhere
- No side effects
- During invocation periods easy to kill virus
- No need go hospitals
- No need more money
- In normal life everywhere available in the form of heather etc.

This method is very important for prevent corona virus along with some antivirus drugs and NSAIDs drugs like paracetamol, aceclofenac, etc.

RESULT :- after observed I show lot's of patients recovered from covid-19 disease. Because dry heat kill virus at the entering time. With take some medicine for fast recover like paracetamol, amoxicillin, phenylephrine, tramadol in chronic pain, in normal pain aceclofenac is sufficient.

Note: **dry heat temperature (60-150C°) depend on our body system. If you can consume high temperature is better for you .**

Timing in every 6 Hours take dry heat 10-30 minutes in interval.

CONCLUSION:- after the review articles & books or case reports we finalize to fight covid-19 & stop disease to spread in the world. Dry heat is Very good to kill virus & no Risk to damage GIT as well mouth ulcer it's a safely use along with paracetamol, IMMUNOBOSTER etc.

ACKNOWLEDGEMENT:-

I would Like Thank from the entire team to Mr. Nilesh kushwah Sir CLINICAL RESEARCH ASSOCIATE TRAINEE (CLINOCARE CR) & National Treasurer NFPS, India for final visualization of manuscript and helping me for designed the protocol all contributors are thankful to Mr. Kushwah for time to time support during the study.

Conflict of interest :

Nil

Funding

None

Abbreviation

covid-19- Corona virus Disease 2019. PCM- PARACETAMOL.

REFERENCE:-

- 1.Hui DSC, Zumla A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect Dis Clin North Am. 2019 Dec;33(4):869-889. [PMC free article] [PubMed]

- 2. Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East Respiratory Syndrome (MERS). *Infect Dis Clin North Am*. 2019 Dec;33(4):891-905. [[PMC free article](#)] [[PubMed](#)]
- 3. PerlmanPerlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. *Nat Rev Microbiol*. 2009 Jun;7(6):439-50. [[PMC free article](#)] [[PubMed](#)]
- 4. FlaxmanFlaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, Whittaker C, Zhu H, Berah T, Eaton JW, Monod M, Imperial College COVID-19 Response Team. Ghani AC, Donnelly CA, Riley S, Vollmer MAC, Ferguson NM, Okell LC, Bhatt S. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 2020 Aug;584(7820):257-261.[[PubMed](#)]
- 5. ClarkClark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, Sanderson C, McKee M, Troeger C, Ong KL, Checchi F, Perel P, Joseph S, Gibbs HP, Banerjee A, Eggo RM., Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Health*. 2020 Aug;8(8):e1003-e1017. [[PMC free article](#)] [[PubMed](#)]
- 6. ChanChan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. *Trends Microbiol*. 2013 Oct;21(10):544-55. [[PMC free article](#)] [[PubMed](#)]
- 7. ChenChen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J Med Virol*. 2020 Apr;92(4):418-423. [[PMC free article](#)] [[PubMed](#)]
- 8. ChanChan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg Microbes Infect*. 2020;9(1):221-236. [[PMC free article](#)] [[PubMed](#)]
- 9. AndersenAndersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. *Nat Med*. 2020 Apr;26(4):450-452.[[PMC free article](#)] [[PubMed](#)]
- 10. GuoGuo ZD, Wang ZY, Zhang SF, Li X, Li L, Li C, Cui Y, Fu RB, Dong YZ, Chi XY, Zhang MY, Liu K, Cao C, Liu B, Zhang K, Gao YW, Lu B, Chen W. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerg Infect Dis*. 2020 Jul;26(7):1583-1591. [[PMC free article](#)] [[PubMed](#)]
- 11. LauerLauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*. 2020 May 05;172(9):577-582. [[PMC free article](#)] [[PubMed](#)]

- 12. LiLi Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020 Mar 26;382(13):1199-1207. [[PMC free article](#)] [[PubMed](#)]
- 13. BauchBauch CT, Lloyd-Smith JO, Coffee MP, Galvani AP. Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future. *Epidemiology*. 2005 Nov;16(6):791-801. [[PubMed](#)]
- 14. LeiLei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. *Antiviral Res*. 2018 Jan;149:58-74. [[PMC free article](#)] [[PubMed](#)]
- 15 Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLoS Pathog*. 2018 Aug;14(8):e1007236. [[PMC free article](#)] [[PubMed](#)]
- 16. dede Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, Puerro M, González-Rojano E, Pedraza L, de Pablo I, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A, Rodríguez-Miguel A, Rodríguez-Puyol D., MED-ACE2-COVID19 study group. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. *Lancet*. 2020 May 30;395(10238):1705-1714. [[PMC free article](#)] [[PubMed](#)]
- 17. LiLi MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infect Dis Poverty*. 2020 Apr 28;9(1):45. [[PMC free article](#)] [[PubMed](#)]
- 18. SmithSmith JC, Sausville EL, Girish V, Yuan ML, Vasudevan A, John KM, Sheltzer JM. Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract. *Dev Cell*. 2020 Jun 08;53(5):514-529.e3. [[PMC free article](#)] [[PubMed](#)]
- 19. HoffmannHoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020 Apr 16;181(2):271-280.e8. [[PMC free article](#)] [[PubMed](#)]
- 20. AngelettiAngeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. *J Med Virol*. 2020 Jun;92(6):584-588.